Business

Data From HERITAGE Confirm PK Biosimilarity for Ogivri

January 9th 2021

By Tony Hagen

Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.

Economists Probe Cost-Effectiveness of Biosimilars

January 7th 2021

By Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4th 2021

By Tony Hagen

Article

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Alvotech Breaks Ground for Biosimilar Development Facility

January 3rd 2021

By Tony Hagen

Article

An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.

Innovent Biologics Gains NMPA Approval for Additional Sulinno Indications

December 31st 2020

By Tony Hagen

Article

China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.

A Review of the Most-Read Biosimilar Stories of 2020: Part 2

December 27th 2020

By Tony Hagen

Article

In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.

Pandemic Delays FDA Decision on Biocon's Bevacizumab Application

December 26th 2020

By Tony Hagen

Article

MYL-14020 could have been the fourth US biosimilar approved by the end of 2020, but the FDA hasn't been able to complete a necessary foreign inspection, owing to the pandemic.

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24th 2020

By Tony Hagen

Article

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Amgen's Bourdon Discusses Riabni Rollout in the United States

December 23rd 2020

By Tony Hagen

Article

Christophe Bourdon, senior vice president and general manager of US Oncology for Amgen, discussed the development and marketing plan for the company's newly approved rituximab biosimilar.

AMCP Sets a Course for Biosimilar Promotion

December 22nd 2020

By Tony Hagen

Article

A partnership forum sponsored by the Academy of Managed Care Pharmacy (AMCP) yielded numerous ideas for improving access to biosimilars.